Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Sees Significant Decrease in Short Interest

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNMGet Rating) was the recipient of a large decrease in short interest in the month of April. As of April 30th, there was short interest totalling 927,200 shares, a decrease of 30.8% from the April 15th total of 1,340,000 shares. Based on an average daily volume of 818,000 shares, the short-interest ratio is presently 1.1 days.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. increased its holdings in Actinium Pharmaceuticals by 21.8% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 8,381 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 1,500 shares in the last quarter. BlackRock Inc. lifted its position in Actinium Pharmaceuticals by 1.1% during the first quarter. BlackRock Inc. now owns 230,950 shares of the biotechnology company’s stock valued at $1,180,000 after buying an additional 2,618 shares in the last quarter. Bank of America Corp DE lifted its position in Actinium Pharmaceuticals by 20.1% during the fourth quarter. Bank of America Corp DE now owns 23,904 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 3,995 shares in the last quarter. Blair William & Co. IL lifted its position in Actinium Pharmaceuticals by 5.5% during the fourth quarter. Blair William & Co. IL now owns 86,866 shares of the biotechnology company’s stock valued at $522,000 after buying an additional 4,500 shares in the last quarter. Finally, Interchange Capital Partners LLC lifted its position in Actinium Pharmaceuticals by 43.8% during the third quarter. Interchange Capital Partners LLC now owns 16,420 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 8.63% of the company’s stock.

Shares of NYSEAMERICAN ATNM traded up $0.24 during midday trading on Friday, hitting $5.75. The company had a trading volume of 548,596 shares, compared to its average volume of 623,807. Actinium Pharmaceuticals has a twelve month low of $4.41 and a twelve month high of $10.30.

ATNM has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 12th. Zacks Investment Research cut shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, February 15th.

About Actinium Pharmaceuticals (Get Rating)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.

Read More

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.